Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib plus Trametinib in KRAS-mutant NSCLC
NCT02230553Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Oct 2014
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lapatinib, trametinib in non-small cell lung cancer (NSCLC), sponsored by Netherlands Cancer Institute. Started Oct 2014; status: completed.
02
Drugs
lapatinibtrametinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02230553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02230553.